1001 related articles for article (PubMed ID: 11480490)
1. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
2. The QT interval and torsade de pointes.
Moss AJ
Drug Saf; 1999; 21 Suppl 1():5-10; discussion 81-7. PubMed ID: 10597863
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps.
Hreiche R; Morissette P; Turgeon J
Gend Med; 2008 Jun; 5(2):124-35. PubMed ID: 18573480
[TBL] [Abstract][Full Text] [Related]
5. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
[TBL] [Abstract][Full Text] [Related]
6. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
8. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
10. [Drug induced QT prolongation].
Altmann D; Eggmann U; Ammann P
Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
[TBL] [Abstract][Full Text] [Related]
11. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
12. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
Lu HR; Remeysen P; De Clerck F
J Cardiovasc Pharmacol; 2000 Dec; 36(6):728-36. PubMed ID: 11117372
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
15. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
Gupta A; Lawrence AT; Krishnan K; Kavinsky CJ; Trohman RG
Am Heart J; 2007 Jun; 153(6):891-9. PubMed ID: 17540188
[TBL] [Abstract][Full Text] [Related]
16. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Briasoulis A; Agarwal V; Pierce WJ
Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
[TBL] [Abstract][Full Text] [Related]
17. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Taylor D
CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
[TBL] [Abstract][Full Text] [Related]
18. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
Cubeddu LX
Am J Ther; 2003; 10(6):452-7. PubMed ID: 14624285
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of drug induced QT interval prolongation.
Ponte ML; Keller GA; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]